Mitral Stenosis

Mitral stenosis (MS) is a valvular heart disease characterized by a narrowing of the mitral valve orifice, impeding blood flow from the left atrium to the left ventricle. This obstruction leads to increased pressure in the left atrium, subsequently causing left atrial enlargement, pulmonary venous congestion, pulmonary hypertension, and eventually right-sided heart failure. The most common cause worldwide is rheumatic fever.

The primary cause of mitral stenosis is rheumatic heart disease, a sequela of acute rheumatic fever following untreated Group A streptococcal pharyngitis. Other less common etiologies include:

• Congenital mitral stenosis: Rare, present at birth.


• Mitral annular calcification: Degenerative process, often seen in elderly patients, which can extend to the leaflets.


• Carcinoid syndrome: Deposition of fibrous tissue on the valve.


• Systemic lupus erythematosus (SLE): Libman-Sacks endocarditis.


• Fabry disease: A lysosomal storage disorder.

The narrowed mitral valve orifice increases resistance to left ventricular (LV) filling during diastole. This leads to a pressure gradient across the mitral valve, with significantly elevated left atrial (LA) pressure. To overcome this resistance, the left atrium hypertrophies and dilates. Sustained high LA pressure transmits backward to the pulmonary veins and capillaries, causing pulmonary venous hypertension and congestion. Chronic pulmonary hypertension results in adaptive changes in the pulmonary vasculature, increasing pulmonary vascular resistance, which places an afterload burden on the right ventricle (RV). Over time, the right ventricle hypertrophies and eventually dilates, leading to right-sided heart failure. Decreased LV preload due to reduced transvalvular flow can lead to lower cardiac output. Atrial fibrillation often develops due to chronic LA stretch.

Mitral stenosis predominantly affects individuals in developing countries where rheumatic fever remains endemic. Globally, it accounts for a significant portion of acquired valvular heart disease. Rheumatic MS is more common in women, with a female-to-male ratio of approximately 2:1, and typically manifests between the ages of 20 and 50 years. Degenerative mitral annular calcification with stenosis is more prevalent in the elderly population.

• History of acute rheumatic fever.
• Geographical location (developing countries, areas with poor access to healthcare).
• Female gender (for rheumatic MS).
• Advanced age (for degenerative calcific MS).
• Recurrent streptococcal pharyngitis (without proper treatment).

A. Early Symptoms

• Exertional dyspnea


• Fatigue


• Reduced exercise tolerance B. Common Symptoms


• Progressive dyspnea (orthopnea, paroxysmal nocturnal dyspnea)


• Palpitations (often due to atrial fibrillation)


• Hemoptysis (due to ruptured bronchial veins or pulmonary congestion)


• Chest pain (atypical, sometimes angina-like)


• Hoarseness (Ortner's syndrome, due to compression of recurrent laryngeal nerve by dilated LA or pulmonary artery)


• Systemic emboli (e.g., stroke, limb ischemia) C. Advanced Symptoms


• Peripheral edema


• Ascites


• Hepatomegaly


• Anasarca (generalized swelling)


• Dyspnea at rest D. Emergency Symptoms


• Acute pulmonary edema


• Sudden onset severe dyspnea


• Symptoms of stroke or acute limb ischemia (due to systemic embolism)

• Inspection: Malar flush (pinkish-purple patches on cheeks), signs of right heart failure (jugular venous distension, peripheral edema).
• Palpation: Tapping apex beat (palpable S1), right ventricular heave (if pulmonary hypertension is severe), thrill at the apex (diastolic rumble).

• Opening snap (OS) (abrupt halt of leaflet motion after rapid early diastolic filling).
• Low-pitched, rumbling diastolic murmur, best heard at the apex with the bell of the stethoscope in the left lateral decubitus position.
• Pre-systolic accentuation of the murmur if in sinus rhythm.
• Pulmonary hypertension signs: prominent P2, tricuspid regurgitation murmur, pulmonary regurgitation murmur (Graham Steell murmur).

A. Clinical Assessment: Detailed history of symptoms, particularly dyspnea and palpitations, and a thorough physical examination.
B. Laboratory Testing: Not primary for diagnosis but useful for assessing complications and differential diagnosis.
C. Imaging Studies: Echocardiography is the cornerstone.
D. Functional Tests: Exercise testing may be used in asymptomatic patients to unmask symptoms or assess hemodynamic response.
E. Biopsy Findings: Not typically used for diagnosis of mitral stenosis.
F. Genetic Testing: Rarely indicated, primarily for very rare congenital forms.
G. Differential Diagnosis: Atrial myxoma, tricuspid stenosis, aortic regurgitation with Austin Flint murmur, restrictive cardiomyopathy.

Complete Blood Count (CBC)
Type: Blood Test
Purpose: Assess for anemia or polycythemia.
Expected Findings: May be normal, or mild anemia, or polycythemia (rarely).
Interpretation: Anemia can exacerbate dyspnea; polycythemia can increase thrombotic risk. B-type Natriuretic Peptide (BNP)/N-terminal pro-BNP
Type: Blood Test
Purpose: Assess heart failure severity and prognosis.
Expected Findings: Elevated levels, correlating with LA pressure and CHF severity.
Interpretation: Higher levels indicate increased cardiac strain and worse prognosis. Rheumatic Fever Markers (ASO titer, Anti-DNase B)
Type: Blood Test
Purpose: Confirm recent streptococcal infection if rheumatic etiology is suspected.
Expected Findings: Elevated.
Interpretation: Suggests recent or past Group A streptococcal infection as the underlying cause. Thyroid Function Tests
Type: Blood Test
Purpose: Rule out hyperthyroidism, which can cause palpitations and exacerbate AF.
Expected Findings: Normal or abnormal (hyperthyroidism).
Interpretation: Hyperthyroidism can worsen cardiac symptoms and AF.

Echocardiography (Transthoracic Echocardiogram - TTE)
Purpose: Gold standard for diagnosis and assessment of MS severity.
Typical Findings: Thickened, restricted mitral valve leaflets, reduced valve area (MVA < 1.5 cm² for moderate, < 1.0 cm² for severe), increased transvalvular pressure gradient, enlarged left atrium, pulmonary hypertension, assessment of right ventricular function.
Clinical Importance: Directly visualizes valve morphology, quantifies stenosis severity, evaluates hemodynamics and associated cardiac chambers. Transesophageal Echocardiography (TEE)
Purpose: Provides clearer images of the mitral valve and left atrium, especially for detecting LA thrombus before intervention.
Typical Findings: Same as TTE but with higher resolution, particularly for LA appendage.
Clinical Importance: Essential for excluding LA thrombus prior to percutaneous mitral commissurotomy. Chest X-ray (CXR)
Purpose: Assess for cardiac chamber enlargement and pulmonary vascular congestion.
Typical Findings: Left atrial enlargement (straightening of the left heart border, double density sign, splaying of the carina), pulmonary venous congestion, interstitial or alveolar edema, right ventricular enlargement.
Clinical Importance: Provides an initial overview of cardiac size and pulmonary status. Electrocardiogram (ECG)
Purpose: Evaluate for chamber enlargement and arrhythmias.
Typical Findings: Left atrial enlargement ("P mitrale" - broad, notched P waves in lead II, biphasic P in V1), atrial fibrillation, signs of right ventricular hypertrophy (tall R in V1).
Clinical Importance: Identifies common complications like atrial fibrillation and provides clues to chronic pressure overload.

• Left Atrial Myxoma: Can produce similar symptoms and a diastolic murmur; distinguished by echocardiography.
• Tricuspid Stenosis: Rarer, usually associated with rheumatic heart disease; distinguished by location and quality of murmur and echo.
• Severe Aortic Regurgitation (Austin Flint Murmur): A diastolic murmur at the apex that can mimic MS; differentiated by absence of opening snap and specific AR findings on echo.
• Restrictive Cardiomyopathy: Causes diastolic dysfunction and heart failure symptoms but without primary valvular disease; differentiated by echocardiography and other diagnostic tests.
• Pulmonary Hypertension from other causes: Differentiated by absence of mitral valve pathology.

• Atrial Fibrillation: Most common arrhythmia, caused by chronic LA stretch, significantly increases risk of systemic embolism.
• Systemic Embolism: Due to thrombus formation in the enlarged, often fibrillating left atrium, leading to stroke, limb ischemia, or other organ damage.
• Pulmonary Hypertension: Chronic elevation of pulmonary arterial pressure, can lead to right heart failure.
• Right Heart Failure: Manifests as peripheral edema, ascites, hepatomegaly.
• Acute Pulmonary Edema: Due to sudden increase in LA pressure.
• Infective Endocarditis: Though less common than in mitral regurgitation, can occur.
• Hemoptysis: From ruptured bronchial veins due to high pulmonary pressure.

A. Lifestyle Modifications

• Sodium restriction and fluid management to reduce pulmonary congestion.


• Regular, non-strenuous exercise in mild cases; avoid vigorous activity in severe MS. B. Preventive Measures


• Rheumatic fever prophylaxis (long-term antibiotics, typically penicillin) in patients with a history of rheumatic fever to prevent recurrence and progression of valve disease. C. Medical Treatment


• Diuretics: (e.g., Furosemide, Hydrochlorothiazide) Reduce pulmonary and systemic congestion.


• Beta-blockers or Calcium Channel Blockers (non-dihydropyridine): (e.g., Metoprolol, Diltiazem) Control heart rate, especially in atrial fibrillation, to prolong diastolic filling time and optimize cardiac output.


• Anticoagulation: (e.g., Warfarin, DOACs - direct oral anticoagulants) Indicated for patients with atrial fibrillation, prior systemic embolism, or dense spontaneous echo contrast in the left atrium. Warfarin is preferred over DOACs for moderate-to-severe MS with AF.


• Antibiotic Prophylaxis: For infective endocarditis in specific high-risk situations (e.g., prior endocarditis, prosthetic valves). D. Surgical Treatment


• Open Mitral Commissurotomy: Surgical repair of the valve, splitting fused leaflets, typically for severe symptomatic MS without significant calcification or subvalvular disease.


• Mitral Valve Replacement (MVR): Indicated for severe MS with significant calcification, subvalvular fusion, or failed percutaneous/surgical commissurotomy. E. Interventional Procedures


• Percutaneous Transvenous Mitral Commissurotomy (PTMC / Percutaneous Balloon Mitral Valvuloplasty - PBMV): Preferred treatment for suitable patients with symptomatic severe MS (MVA <1.5 cm²) who have favorable valve anatomy (non-calcified, pliable leaflets, no significant subvalvular disease, no left atrial thrombus). F. Rehabilitation


• Cardiac rehabilitation programs can aid in recovery and functional improvement post-intervention. G. Emergency Management


• For acute pulmonary edema: IV diuretics, oxygen, nitrates.


• For rapid atrial fibrillation: Rate control with IV beta-blockers or calcium channel blockers.


• For systemic embolism: Anticoagulation, and management of stroke/ischemia as appropriate.

The prognosis of mitral stenosis varies depending on its severity, the presence of complications like atrial fibrillation and pulmonary hypertension, and the timing of intervention. Untreated severe MS leads to progressive symptoms, heart failure, and reduced life expectancy, with a median survival of 2-5 years after severe symptoms develop. Early diagnosis and timely intervention, especially PTMC in suitable candidates, can significantly improve symptoms, functional capacity, and long-term outcomes.

• Primary Prevention: Prompt and adequate treatment of streptococcal pharyngitis (e.g., with penicillin) to prevent acute rheumatic fever, particularly in endemic areas.
• Secondary Prevention: Long-term antibiotic prophylaxis in individuals with a history of acute rheumatic fever to prevent recurrent episodes and subsequent progressive valvular damage.

The following homeopathic remedies have been historically indicated for symptoms associated with Mitral Stenosis. Selection should be based on individualized symptom totality and constitutional assessment.

• Homeopathy by Hadhrat Mirza Tahir Ahmad (r.a.) — Primary clinical reference
• Robin Murphy — Lotus Materia Medica (3rd Edition)
• William Boericke — Pocket Manual of Homœopathic Materia Medica & Repertory
• ICD-10/ICD-11 Classification — World Health Organization
• Harrison's Principles of Internal Medicine (Reference Standard)

This clinical reference profile is compiled from authoritative medical sources for educational purposes. Always verify clinical data with current medical guidelines.

🔬 Lab Report Analyzer (Diagnostic Verification)

Upload your laboratory bloodwork PDF or paste your report text to automatically extract markers, detect units, and identify reference range variances related to Mitral Stenosis.